Polypeptide is a linear organic polymer consisting of a large number of amino-acid residues bonded together in a chain, forming part of (or the whole of) a protein molecule. As a raw material, polypeptide is widely used in pharmaceutical, food, and cosmetics industries.
Polypeptide market is mainly controlled by foreign powerful pharmaceutical enterprises. Compared to international market, China’s polypeptide drug industry development is still in the start stage. Problems presently existing in China polypeptide market include backward production technique, small scale, shortage of research and development ability, weak technological innovation ability, etc. But with the national policy support in recent years, Chinese enterprises and scientific research institutions have increased investment in the research and development of polypeptide drug.
China’s polypeptide drug industry market size has showed a steady increase from 2014 to 2018. In 2018, it reached about 77.4 billion Yuan, increased by 78%.
With the advancement of China's polypeptide production technology, polypeptide output has increased a lot. In 2018, the output of polypeptide drug industry market reached about 200 MT. Besides, the market demand was about 194 MT in 2018.
In terms of the company size, China’s polypeptide companies are mainly small and medium-sized enterprises, accounting for 63.3%. And in terms of the company nature, foreign commercial enterprises and enterprises with Hong Kong and Macao investment accounted for a large proportion of 47.4%.